Biotricity Inc. (OTCQB: BTCY) announced its financial results for the second quarter of fiscal year 2025, ended September 30, 2024. The company achieved positive Adjusted EBITDA for the month of September 2024, marking a historical first.
For Q2 FY2025, Adjusted EBITDA improved to negative $249,000, representing an 87% reduction in negative Adjusted EBITDA compared to the prior year period. This demonstrates significant progress towards overall profitability.
The company reported year-over-year revenue growth and improvements across key operating metrics, including recurring technology fees, device sales, and gross margins. These results reflect Biotricity's focus on automation, operational efficiency, and financial discipline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.